2022
Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline imagesThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseQuantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation
Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica 2020, 61: 1708-1716. PMID: 32216452, PMCID: PMC7529766, DOI: 10.1177/0284185120909964.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedNeoplasm StagingRadiography, InterventionalRetrospective StudiesSensitivity and SpecificityTumor BurdenUltrasonography, InterventionalConceptsProgression-free survivalTotal tumor volumeRenal cell carcinomaCell carcinomaOdds ratioTumor volumeImaging biomarkersImage-guided thermal ablationPrognosis of patientsRENAL nephrometry scoreCox regression modelLargest tumor diameterLog-rank testKaplan-Meier plotsCross-sectional imagingSensitive imaging biomarkerMetastatic diseaseSecondary outcomesPrimary outcomeDistant metastasisNephrometry scoreTumor diameterOutcome parametersLesion vascularityTNM stage
2019
Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization
Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. Journal Of Nuclear Medicine 2019, 60: 1066-1072. PMID: 30655331, PMCID: PMC6681698, DOI: 10.2967/jnumed.118.219691.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBiomarkersCarcinoma, HepatocellularEmbolization, TherapeuticFeasibility StudiesFemaleHumansImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMicrospheresMiddle AgedMultimodal ImagingPrognosisRegression AnalysisRetrospective StudiesTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNon-HCC patientsTransarterial radioembolizationHepatocellular carcinomaBaseline imagingTumor responseTumor volumeChild-Pugh class B patientsBaseline imaging featuresClass B patientsNormal liver ratiosTotal tumor volumeSPECT/CTContrast-enhanced MRIQuantitative European AssociationMultiphasic contrast-enhanced MRIInstitutional review boardHigh TNRPreprocedural MRIChild-PughB patientsLiver criteriaTumor burdenClinical parametersHepatic malignanciesRetrospective study
2018
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma.
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal Of Visualized Experiments 2018 PMID: 30371657, PMCID: PMC6235502, DOI: 10.3791/58382.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyN patientsHepatocellular carcinomaTrans-arterial therapiesIntra-arterial treatmentCohort of patientsStandard of careLikelihood of responseClinical research questionsSurgical resectionNew patientsTreatment responseUnivariate associationsPatientsTraining patientsInterventional radiologyTherapyCarcinomaTreatmentImage-guided therapyOutcomesFinal modelImaging dataResectionResponse
2017
The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging 2017, 46: 1-7. PMID: 28668723, PMCID: PMC5720941, DOI: 10.1016/j.clinimag.2017.05.007.Peer-Reviewed Original ResearchConceptsEarly response assessmentTransarterial chemoembolizationImaging-based criteriaResponse assessmentHepatocellular carcinomaTumor response assessmentAnti-angiogenic therapyQuantitative European AssociationTherapy armOverall survivalLiver criteriaAntiangiogenic therapyTreatment groupsPatientsSimilar associationEuropean AssociationBevacizumabChemoembolizationCarcinomaTherapyAssociationAssessmentFollowCriteriaBaseline
2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology 2016, 27: 526-535. PMID: 27277261, PMCID: PMC5470590, DOI: 10.1007/s00330-016-4445-9.Peer-Reviewed Original ResearchConceptsMedian overall survivalPortal venous thrombosisAdvanced-stage hepatocellular carcinomaConventional TACEDEB-TACEHepatocellular carcinomaOverall survivalAdverse eventsBeads TACEDrug-eluting bead transcatheter arterial chemoembolizationConventional trans-arterial chemoembolizationPropensity scoreDrug-eluting beads TACECommon adverse eventsConclusionOur retrospective studyEqual safety profileChild-Pugh classMethodsThis retrospective analysisPortal vein thrombosisPost-embolization syndromeTranscatheter arterial chemoembolizationStage hepatocellular carcinomaTrans-arterial chemoembolizationSub-group analysisArterial chemoembolization3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology 2016, 26: 3243-3252. PMID: 26762942, PMCID: PMC4942412, DOI: 10.1007/s00330-015-4168-3.Peer-Reviewed Original ResearchConceptsHazard ratioOverall survivalTransarterial chemoembolizationBaseline MRIHepatocellular carcinomaTumor burdenDominant lesionTumor assessmentTumor volumeMultivariate cox proportional hazard ratiosCox proportional hazard ratiosCurrent radiological methodMethodsThis retrospective analysisProportional hazard ratiosBCLC staging systemKaplan-Meier plotsTumor diameterPatient survivalStaging systemHCC patientsMultiple lesionsLiver volumeRetrospective analysisLesion assessmentPatients
2015
3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma
Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. European Radiology 2015, 26: 849-857. PMID: 26139318, PMCID: PMC4698362, DOI: 10.1007/s00330-015-3895-9.Peer-Reviewed Original ResearchConceptsSingle-session stereotactic radiosurgeryTotal tumor volumeSignificant tumor shrinkageVestibular schwannomaTumor shrinkageStereotactic radiotherapyTumor volumeRadiation therapyStereotactic radiosurgeryT1-weighted contrast-enhanced MRISubsequent microsurgical resectionTumor-related symptomsSporadic vestibular schwannomaContrast-enhanced MRIFSRT groupRadiological progressionMicrosurgical resectionClinical outcomesSRS groupRetrospective analysisResponse assessmentPatientsVolumetric assessmentFSRTSchwannomaComparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology 2015, 278: 275-84. PMID: 26131913, PMCID: PMC4695977, DOI: 10.1148/radiol.2015142951.Peer-Reviewed Original ResearchIntraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. CardioVascular And Interventional Radiology 2015, 38: 1548-1556. PMID: 26001366, PMCID: PMC4651808, DOI: 10.1007/s00270-015-1129-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyContrast MediaEthiodized OilFemaleFollow-Up StudiesHumansImage EnhancementImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsLipiodol depositionConventional transarterial chemoembolizationTumor responseOverall tumor volumeTumor volumeCE-MRIHepatocellular carcinomaTransarterial chemoembolizationTumor necrosisContrast-enhanced magnetic resonance imagingNecrotic tumour volumeResponse Evaluation CriteriaT-testMagnetic resonance imagingStudent's t-testMethodsThis IRBTarget lesionsRetrospective analysisSolid tumorsResonance imagingSpearman rank-order correlationPatientsCone-beam CTCBCTChemoembolizationRadiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement
Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. European Radiology 2015, 26: 103-113. PMID: 25994198, PMCID: PMC4654989, DOI: 10.1007/s00330-015-3812-2.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationHCC patientsIpsilateral placementTumor enhancementHepatocellular carcinoma patientsROI placementContrast-enhanced MR imagingRadiologic-pathologic analysisArterial chemoembolizationCarcinoma patientsPathological correlationIntra-class correlationPatientsMR imagingClinical methodsMedian differencePathologyInterest placementHistopathologyA new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization
Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. European Radiology 2015, 25: 3255-3262. PMID: 25956933, PMCID: PMC4595540, DOI: 10.1007/s00330-015-3717-0.Peer-Reviewed Original ResearchConceptsDose area productDigital subtraction angiographyTransarterial chemoembolizationCone-beam CTRadiation exposureLiver cancerDSA image qualityCumulative dose area productSecondary liver cancerLiver cancer patientsTwo-arm trialSignificant differencesResultsBoth cohortsDiagnostic image qualityPatient characteristicsConsecutive patientsTumor burdenTACE proceduresCancer patientsSubtraction angiographyPatientsHIPAA compliantDigital fluoroscopyProcedure courseIndependent readersMultimodality 3D Tumor Segmentation in HCC Patients Treated with TACE
Wang Z, Chapiro J, Schernthaner R, Duran R, Chen R, Geschwind JF, Lin M. Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE. Academic Radiology 2015, 22: 840-845. PMID: 25863795, PMCID: PMC4464945, DOI: 10.1016/j.acra.2015.03.001.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overAlgorithmsAntibiotics, AntineoplasticCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyDoxorubicinFemaleHumansImage EnhancementImage Interpretation, Computer-AssistedImaging, Three-DimensionalKidney NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMultidetector Computed TomographyMultimodal ImagingPattern Recognition, AutomatedPrognosisReproducibility of ResultsRetrospective StudiesSensitivity and SpecificitySubtraction TechniqueTreatment OutcomeEarly survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver
Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. European Radiology 2015, 25: 1993-2003. PMID: 25636420, PMCID: PMC4458393, DOI: 10.1007/s00330-015-3595-5.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyColorectal liver metastasesTransarterial chemoembolizationPatient survivalHazard ratioLiver metastasesOverall survivalResponse assessmentVolumetric tumour response assessmentCox proportional hazard ratiosMethodsThis retrospective analysisProportional hazard ratiosKaplan-Meier analysisColorectal cancer metastasisTumor response assessmentTumor analysisEarly survival predictionQuantitative MRI assessmentMRI assessmentTumor responseLesion volumeRetrospective analysisMultivariate analysisPatientsPredictive roleThree-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging
Chapiro J, Duran R, Lin M, Werner JD, Wang Z, Schernthaner R, Savic LJ, Lessne ML, Geschwind JF, Hong K. Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging. Journal Of Vascular And Interventional Radiology 2015, 26: 670-678.e2. PMID: 25638750, PMCID: PMC4414730, DOI: 10.1016/j.jvir.2014.11.020.Peer-Reviewed Original Research
2014
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers
Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers. Radiology 2014, 275: 438-47. PMID: 25531387, PMCID: PMC4409467, DOI: 10.1148/radiol.14141180.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaTumor diameterHazard ratioTumor responseTumor volumeResponse rateCox proportional hazard ratiosStaging markersTumor response rateProportional hazard ratiosResponse Evaluation CriteriaSurvival of patientsKaplan-Meier analysisSingle-institution analysisBaseline magnetic resonance imagesHigh response rateInstitutional review boardOverall survivalLiver (EASL) guidelinesPatient cohortImaging markerRadiologic measurementsLarge lesions